Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$0.331
−$0.0005 · -0.15%
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Previous close
$0.331
−$0.0005 · -0.15%
After-hours
$0.3473
+$0.0163 · +4.92%
Sep 16, 7:44 PM ET
Regular session · ET · Market data may be delayed.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Day range
Current $0.331
52-week range
Current $0.331
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
10
Overpriced
Sentiment
58
Mixed
Risk
91
Extreme Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Day range
Current $0.331
52-week range
Current $0.331
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 431.61K USD | 136.64K USD | 1.36M USD | 10.25M USD | 9.89M USD |
| Cost of goods sold | 100.13K USD | 130.64K USD | 1.31M USD | 4.73M USD | 5.14M USD |
| Gross profit | 331.48K USD | 6.01K USD | 49.03K USD | 5.52M USD | 4.75M USD |
| Research and development | 1.96M USD | 2.24M USD | 100.28K USD | 993.19K USD | 899.71K USD |
| Selling, general, and administrative | 14.52M USD | 12.05M USD | 4.45M USD | 6.57M USD | 7.54M USD |
| Operating expenses | 16.58M USD | 14.71M USD | 4.45M USD | 8.44M USD | 10.04M USD |
| Interest income | 302.7K USD | 135.34K USD | 4.2K USD | 20.99K USD | — |
| Interest expense | 4.08M USD | 1.34M USD | 1.14M USD | 336.21K USD | 23.59K USD |
| Depreciation and amortization | 491.78K USD | 53.36K USD | 1.05M USD | 194.7K USD | 138.91K USD |
| Operating income | −16.24M USD | −14.7M USD | −4.4M USD | −2.92M USD | −5.29M USD |
| Net income | −41.51M USD | 9.07M USD | −17.84M USD | −3.47M USD | −5.32M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
